Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer

It may be possible to achieve insulin sensitivity through the recently identified mitochondrial target of thiazolidinediones (mTOT), thereby avoiding peroxisome proliferator–activated receptor-γ (PPAR-γ)-dependent side effects. In this phase IIb clinical trial, 258 patients with type 2 diabetes comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Colca, J R, VanderLugt, J T, Adams, W J, Shashlo, A, McDonald, W G, Liang, J, Zhou, R, Orloff, D G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604641/
https://www.ncbi.nlm.nih.gov/pubmed/23462886
http://dx.doi.org/10.1038/clpt.2013.10

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604641/
https://www.ncbi.nlm.nih.gov/pubmed/23462886
http://dx.doi.org/10.1038/clpt.2013.10

Ejemplares similares